{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:08:07Z","timestamp":1774512487851,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>After heart transplantation, calcineurin inhibitors (CNI) (cyclosporin A and tacrolimus) are key immunosuppressive drugs to prevent graft rejection. Whole-blood concentration (C<jats:sub>blood<\/jats:sub>)-guided therapeutic drug monitoring (TDM) is systematically performed to improve graft outcomes. However, some patients will still experience graft rejection and\/or adverse events despite CNI C<jats:sub>blood<\/jats:sub> within the therapeutic range. Other pharmacokinetic parameters, such as the intragraft, or intracellular concentration at the CNI site of action could refine their TDM. Nonetheless, these remain to be explored. The objective of the INTRACAR study was to describe the relationship between whole blood, intragraft, and intracellular CNI concentrations as well as their efficacy in heart transplant recipients (HTR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In a cohort of HTR, protocol endomyocardial biopsies (EMB) were collected to assess rejection by anatomopathological analysis. Part of the EMB was used to measure the intragraft concentrations of CNI (C<jats:sub>EMB<\/jats:sub>). C<jats:sub>blood<\/jats:sub> and the concentration inside peripheral blood mononuclear cells, (C<jats:sub>PBMC<\/jats:sub>), a cellular fraction enriched with lymphocytes, were also monitored. Concentrations in the 3 matrices were compared between patients with and without biopsy-proven acute rejection (BPAR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirty-four HTR were included, representing nearly 100 pharmacokinetic (PK) samples for each CNI. C<jats:sub>blood<\/jats:sub>, C<jats:sub>EMB<\/jats:sub>, and C<jats:sub>PBMC<\/jats:sub> correlated for both CNI. BPAR was observed in 74 biopsies (39.6%) from 26 patients (76.5%), all except one was of low grade. None of the PK parameters (C<jats:sub>blood<\/jats:sub>, C<jats:sub>EMB<\/jats:sub>, C<jats:sub>PBMC<\/jats:sub>, C<jats:sub>EMB\/blood<\/jats:sub>, and C<jats:sub>PBMC\/blood<\/jats:sub>) was associated with BPAR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In this cohort of well-immunosuppressed patients, no association was observed for any of the PK parameters, including C<jats:sub>blood<\/jats:sub>, with the occurrence of BPAR. However, a trend was noticed for the C<jats:sub>EMB<\/jats:sub> and C<jats:sub>EMB\/blood<\/jats:sub> of cyclosporin A. Further studies in higher-risk patients may help optimize the use of C<jats:sub>EMB<\/jats:sub> and C<jats:sub>PBMC<\/jats:sub> for CNI TDM in HTR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001025","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T16:01:43Z","timestamp":1661443303000},"page":"229-235","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Blood, Cellular, and Tissular Calcineurin Inhibitors Pharmacokinetic\u2013Pharmacodynamic Relationship in Heart Transplant Recipients: The INTRACAR Study"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-5629","authenticated-orcid":false,"given":"Gwendal","family":"Coste","sequence":"first","affiliation":[{"name":"Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail)\u2014UMR S 1085, EHESP, Inserm, CHU Rennes;"},{"name":"INSERM, Centre d\u2019Investigation Clinique;"},{"name":"Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Chabanne","sequence":"additional","affiliation":[{"name":"Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Tron","sequence":"additional","affiliation":[{"name":"Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail)\u2014UMR S 1085, EHESP, Inserm, CHU Rennes;"},{"name":"INSERM, Centre d\u2019Investigation Clinique;"},{"name":"Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Lelong","sequence":"additional","affiliation":[{"name":"Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"additional","affiliation":[{"name":"Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail)\u2014UMR S 1085, EHESP, Inserm, CHU Rennes;"},{"name":"INSERM, Centre d\u2019Investigation Clinique;"},{"name":"Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Roussel","sequence":"additional","affiliation":[{"name":"Laboratoire d'h\u00e9matologie, Centre Hospitalier Universitaire de Rennes;"},{"name":"Universit\u00e9 de Rennes, \u00c9tablissement Fran\u00e7ais du Sang (EFS) de Bretagne, Inserm, MICMAC-UMR_S1236;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Le Gall","sequence":"additional","affiliation":[{"name":"Laboratoire d'anatomie et cytologie pathologiques, Centre Hospitalier Universitaire de Rennes;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Turlin","sequence":"additional","affiliation":[{"name":"Laboratoire d'anatomie et cytologie pathologiques, Centre Hospitalier Universitaire de Rennes;"},{"name":"Centre de Ressources Biologiques (CRB) Sant\u00e9 de Rennes BB-0033-00056, Centre Hospitalier Universitaire de Rennes;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Desille-Dugast","sequence":"additional","affiliation":[{"name":"Centre de Ressources Biologiques (CRB) Sant\u00e9 de Rennes BB-0033-00056, Centre Hospitalier Universitaire de Rennes;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwan","family":"Fl\u00e9cher","sequence":"additional","affiliation":[{"name":"INSERM, Centre d\u2019Investigation Clinique;"},{"name":"Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes;"},{"name":"Laboratoire Traitement du Signal et de l'Image (LTSI) unit\u00e9 mixte 1099 INSERM; and"},{"name":"FHU SUPORT, Rennes, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Laviolle","sequence":"additional","affiliation":[{"name":"Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail)\u2014UMR S 1085, EHESP, Inserm, CHU Rennes;"},{"name":"INSERM, Centre d\u2019Investigation Clinique;"},{"name":"Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes;"},{"name":"FHU SUPORT, Rennes, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[{"name":"Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail)\u2014UMR S 1085, EHESP, Inserm, CHU Rennes;"},{"name":"INSERM, Centre d\u2019Investigation Clinique;"},{"name":"Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes;"},{"name":"FHU SUPORT, Rennes, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.healun.2021.07.015","article-title":"The international thoracic organ transplant registry of the international society for heart and Lung transplantation: thirty-eighth adult heart transplantation report\u20142021; focus on recipient characteristics","volume":"40","author":"Khush","year":"2021","journal-title":"J Heart Lung Transpl."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacc.2016.04.033","article-title":"Allograft vasculopathy: the achilles' heel of heart transplantation","volume":"68","author":"Chih","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/14779072.2017.1267565","article-title":"Immunosuppression and adult heart transplantation: emerging therapies and opportunities","volume":"15","author":"Furiasse","year":"2017","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif Organs"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.clinbiochem.2013.02.011","article-title":"Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients","volume":"46","author":"Lemaitre","year":"2013","journal-title":"Clin Biochem."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R8-20250603","first-page":"70","article-title":"Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue","volume":"21","author":"Sandborn","year":"1995","journal-title":"Hepatology"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/FTD.0b013e31805c73f1","article-title":"Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection","volume":"29","author":"Capron","year":"2007","journal-title":"Ther Drug Monit."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/pgs.10.43","article-title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation","volume":"11","author":"Capron","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/bcp.14585","article-title":"Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients","volume":"87","author":"Francke","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","article-title":"Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study","volume":"25","author":"Capron","year":"2012","journal-title":"Transpl Int."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.transproceed.2007.03.103","article-title":"Cyclosporine monitoring in peripheral blood mononuclear cells: feasibility and interest. A prospective study on 20 renal transplant recipients","volume":"39","author":"Lepage","year":"2007","journal-title":"Transpl Proc"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/TP.0b013e31815feede","article-title":"Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients","volume":"85","author":"Falck","year":"2008","journal-title":"Transplantation"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clinbiochem.2014.12.018","article-title":"Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells","volume":"48","author":"Lemaitre","year":"2015","journal-title":"Clin Biochem."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.phrs.2016.07.027","article-title":"Intra-cellular immunosuppressive drugs monitoring: a step forward towards better therapeutic efficacy after organ transplantation?","volume":"111","author":"Capron","year":"2016","journal-title":"Pharmacol Res."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpba.2012.03.042","article-title":"Everolimus quantification in peripheral blood mononuclear cells using ultra high performance liquid chromatography tandem mass spectrometry","volume":"66","author":"Roullet-Renoleau","year":"2012","journal-title":"J Pharm Biomed Anal."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","article-title":"Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection","volume":"24","author":"Stewart","year":"2005","journal-title":"J Heart Lung Transpl."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/FTD.0000000000000780","article-title":"Measuring intracellular concentrations of calcineurin inhibitors: expert consensus from the international association of therapeutic drug monitoring and clinical toxicology expert panel","volume":"42","author":"Lemaitre","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cyto.a.20893","article-title":"Refining the white blood cell differential: the first flow cytometry routine application","volume":"77","author":"Roussel","year":"2010","journal-title":"Cytometry A"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"113664","DOI":"10.1016\/j.jpba.2020.113664","article-title":"A simple and fast liquid chromatography tandem mass spectrometry method to determine cyclosporine A concentrations in endomyocardial biopsies","volume":"193","author":"Tron","year":"2021","journal-title":"J Pharm Biomed Anal."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/FTD.0b013e318236315d","article-title":"Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies-a method suitable for small (<1 mg) samples","volume":"33","author":"Noll","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/FTD.0b013e31828e8162","article-title":"Validation of an LC-MS\/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies","volume":"35","author":"Noll","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/FTD.0000000000000510","article-title":"Determination of tacrolimus concentration and protein expression of P-glycoprotein in single human renal core biopsies","volume":"40","author":"Krogstad","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FTD.0000000000000912","article-title":"Development and validation of A liquid chromatography-tandem mass spectrometry method to simultaneously measure tacrolimus and everolimus concentrations in kidney allograft biopsies after kidney transplantation","volume":"44","author":"Zhang","year":"2022","journal-title":"Ther Drug Monit."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1111\/bcp.14806","article-title":"Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5\/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients","volume":"87","author":"Sallustio","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3390\/pharmaceutics13101576","article-title":"Kidney and liver tissue tacrolimus concentrations in adult transplant recipients-the influence of the whole blood and tissue concentrations on efficiency of treatment during immunosuppressive therapy","volume":"13","author":"Bodnar-Broniarczyk","year":"2021","journal-title":"Pharmaceutics"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/hep.1840150619","article-title":"Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection","volume":"15","author":"Sandborn","year":"1992","journal-title":"Hepatology"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2047-1440-2-5","article-title":"Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients","volume":"2","author":"Robertsen","year":"2013","journal-title":"Transpl Res"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"122215","DOI":"10.1016\/j.jchromb.2020.122215","article-title":"Development and validation of a combined enzymatic-digestion\/mass spectrometry assay for Tacrolimus quantitation in cardiac biopsies","volume":"1152","author":"Molinaro","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"101756","DOI":"10.1016\/j.bpg.2021.101756","article-title":"Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology","volume":"54-55","author":"Udomkarnjananun","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:24:28Z","timestamp":1748971468000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001025","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2022-04-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}